Lilly’s long-acting insulin wins NICE blessing ahead of potential UK approval
For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be…
Pursuing patient options, Novo kicks off trial testing smaller doses of Wegovy pill
Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy…
Novo Nordisk makes Omnicom agency of record for US media buying
Novo Nordisk has made Omnicom the agency of record for U.S. media buying, ending the drugmaker’s six-year partnership…
Obesity not a ‘zero-sum game’ as patients crave optionality, Novo CEO says: Reuters
Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk…
Novo’s Catalent plant ditched in FDA refiling of SMA drug
Scholar Rock has shed Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for…
‘Familiarity’ with oral Wegovy has triggered its quick uptake
What’s been Novo Nordisk’s secret weapon to turn the tables on Eli Lilly and win the current market…
ADA: Novo’s Wegovy pill crosses hefty 3M prescription threshold
For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing…
Novo Nordisk’s ‘optimistic’ CEO Doustdar sits down with Fierce
In the air-conditioned haven of the Hilton just downriver from the American Diabetes Association’s 2026 Scientific Sessions in…
The Oral GLP-1 Tracker: Week 1 of Lilly’s Foundayo launch
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started…
Novo’s security breach claimed by dual hacking groups: reports
After disclosing a security breach last week concerning “a limited number of internal IT systems,” details on the…